These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 30106956

  • 1. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD, Tadesse Z, Gebresillasie S, Shiferaw A, Zerihun M, Emerson PM, Callahan K, Cotter SY, Stoller NE, Porco TC, Oldenburg CE, Lietman TM.
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [Abstract] [Full Text] [Related]

  • 2. Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II).
    Mahmud H, Haile BA, Tadesse Z, Gebresillasie S, Shiferaw A, Zerihun M, Liu Z, Callahan EK, Cotter SY, Varnado NE, Oldenburg CE, Porco TC, Lietman TM, Keenan JD.
    Clin Infect Dis; 2023 Aug 14; 77(3):388-395. PubMed ID: 37021692
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.
    Gebre T, Ayele B, Zerihun M, Genet A, Stoller NE, Zhou Z, House JI, Yu SN, Ray KJ, Emerson PM, Keenan JD, Porco TC, Lietman TM, Gaynor BD.
    Lancet; 2012 Jan 14; 379(9811):143-51. PubMed ID: 22192488
    [Abstract] [Full Text] [Related]

  • 5. Frequency of Mass Azithromycin Distribution for Ocular Chlamydia in a Trachoma Endemic Region of Ethiopia: A Cluster Randomized Trial.
    Lietman TM, Ayele B, Gebre T, Zerihun M, Tadesse Z, Emerson PM, Nash SD, Porco TC, Keenan JD, Oldenburg CE.
    Am J Ophthalmol; 2020 Jun 14; 214():143-150. PubMed ID: 32171768
    [Abstract] [Full Text] [Related]

  • 6. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
    Morberg DP, Alemayehu W, Melese M, Lakew T, Sisay A, Zhou Z, Cevallos V, Oldenburg CE, Porco TC, Lietman TM, Keenan JD.
    Ophthalmic Epidemiol; 2019 Feb 14; 26(1):19-26. PubMed ID: 30153085
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial.
    Arzika AM, Mindo-Panusis D, Abdou A, Kadri B, Nassirou B, Maliki R, Alsoudi AF, Zhang T, Cotter SY, Lebas E, O'Brien KS, Callahan EK, Bailey RL, West SK, Goodhew EB, Martin DL, Arnold BF, Porco TC, Lietman TM, Keenan JD, Macrolides Oraux pour Réduire les Décés Avec un Oeil sur la Resistance (MORDOR)–Niger Study Group.
    JAMA Netw Open; 2022 Aug 01; 5(8):e2228244. PubMed ID: 35997979
    [Abstract] [Full Text] [Related]

  • 9. Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma.
    Amza A, Kadri B, Nassirou B, Arzika AM, Austin A, Nyatigo F, Lebas E, Arnold BF, Lietman TM, Oldenburg CE.
    BMC Ophthalmol; 2021 Jan 06; 21(1):15. PubMed ID: 33407263
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma.
    Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, Cevallos V, Zhou Z, Maxey K, Lee DC, Shapiro BL, Srinivasan M, Porco T, Whitcher JP, Gaynor BD, Lietman TM.
    JAMA; 2006 Mar 08; 295(10):1142-6. PubMed ID: 16522834
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial.
    Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, West SK, Bailey RL, Porco TC, Gaynor BD, Keenan JD, Lietman TM, Oldenburg CE.
    Br J Ophthalmol; 2018 May 08; 102(5):680-686. PubMed ID: 28893761
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B, Gebre T, Moncada J, House JI, Stoller NE, Zhou Z, Porco TC, Gaynor BD, Emerson PM, Schachter J, Keenan JD.
    PLoS Negl Trop Dis; 2011 Dec 08; 5(12):e1441. PubMed ID: 22180804
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK, Munoz B, Mkocha H, Gaydos C, Quinn T.
    Invest Ophthalmol Vis Sci; 2007 Apr 08; 48(4):1492-7. PubMed ID: 17389476
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
    Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P, Gaynor BD, Lietman TM.
    JAMA; 2009 Sep 02; 302(9):962-8. PubMed ID: 19724043
    [Abstract] [Full Text] [Related]

  • 18. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, Quinn T, West SK.
    JAMA Ophthalmol; 2013 Apr 02; 131(4):431-6. PubMed ID: 23392481
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.